Literature DB >> 21793507

Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry.

Priyamvada Acharya1, Cajetan Dogo-Isonagie, Judith M LaLonde, Son N Lam, George J Leslie, Mark K Louder, Leah L Frye, Asim K Debnath, Jeremy R Greenwood, Timothy S Luongo, Loïc Martin, K Shawn Watts, James A Hoxie, John R Mascola, Carole A Bewley, Peter D Kwong.   

Abstract

Tyrosine sulfate-mediated interactions play an important role in HIV-1 entry. After engaging the CD4 receptor at the cell surface, the HIV-1 gp120 glycoprotein binds to the CCR5 co-receptor via an interaction that requires two tyrosine sulfates, at positions 10 and 14 in the CCR5-N terminus. Building on previous structure determinations of this interaction, here we report the targeting of these tyrosine sulfate binding sites for drug design through in silico screening of small molecule libraries, identification of lead compounds, and characterization of biological activity. A class of tyrosine sulfate-mimicking small molecules containing a "phenyl sulfonate-linker-aromatic" motif was identified that specifically inhibited binding of gp120 to the CCR5-N terminus as well as to sulfated antibodies that recognize the co-receptor binding region on gp120. The most potent of these compounds bound gp120 with low micromolar affinity and its CD4-induced conformation with K(D)'s as tight as ∼50 nM. Neutralization experiments suggested the targeted site to be conformationally inaccessible prior to CD4 engagement. Primary HIV-1 isolates were weakly neutralized, preincubation with soluble CD4 enhanced neutralization, and engineered isolates with increased dependence on the N terminus of CCR5 or with reduced conformational barriers were neutralized with IC(50) values as low as ∼1 μM. These results reveal the potential of targeting the tyrosine sulfate interactions of HIV-1 and provide insight into how mechanistic barriers, evolved by HIV-1 to evade antibody recognition, also restrict small-molecule-mediated neutralization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793507      PMCID: PMC3205951          DOI: 10.1021/cb200068b

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  40 in total

Review 1.  Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.

Authors:  Philip M Grant; Andrew R Zolopa
Journal:  Curr Opin Investig Drugs       Date:  2010-08

2.  A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction.

Authors:  Thomas S Rush; J Andrew Grant; Lidia Mosyak; Anthony Nicholls
Journal:  J Med Chem       Date:  2005-03-10       Impact factor: 7.446

3.  Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth.

Authors:  Chih-chin Huang; François Stricher; Loïc Martin; Julie M Decker; Shahzad Majeed; Philippe Barthe; Wayne A Hendrickson; James Robinson; Christian Roumestand; Joseph Sodroski; Richard Wyatt; George M Shaw; Claudio Vita; Peter D Kwong
Journal:  Structure       Date:  2005-05       Impact factor: 5.006

4.  Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4.

Authors:  Chih-Chin Huang; Son N Lam; Priyamvada Acharya; Min Tang; Shi-Hua Xiang; Syed Shahzad-Ul Hussan; Robyn L Stanfield; James Robinson; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Carole A Bewley; Peter D Kwong
Journal:  Science       Date:  2007-09-28       Impact factor: 47.728

5.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Authors:  Yuxing Li; Stephen A Migueles; Brent Welcher; Krisha Svehla; Adhuna Phogat; Mark K Louder; Xueling Wu; George M Shaw; Mark Connors; Richard T Wyatt; John R Mascola
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

6.  Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

Authors:  Patrick Dorr; Mike Westby; Susan Dobbs; Paul Griffin; Becky Irvine; Malcolm Macartney; Julie Mori; Graham Rickett; Caroline Smith-Burchnell; Carolyn Napier; Rob Webster; Duncan Armour; David Price; Blanda Stammen; Anthony Wood; Manos Perros
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

7.  Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor.

Authors:  T Mirzabekov; N Bannert; M Farzan; W Hofmann; P Kolchinsky; L Wu; R Wyatt; J Sodroski
Journal:  J Biol Chem       Date:  1999-10-01       Impact factor: 5.157

8.  Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.

Authors:  Shi-Hua Xiang; Michael Farzan; Zhihai Si; Navid Madani; Liping Wang; Eric Rosenberg; James Robinson; Joseph Sodroski
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

9.  Structure of an unliganded simian immunodeficiency virus gp120 core.

Authors:  Bing Chen; Erik M Vogan; Haiyun Gong; John J Skehel; Don C Wiley; Stephen C Harrison
Journal:  Nature       Date:  2005-02-24       Impact factor: 49.962

10.  Antigenic conservation and immunogenicity of the HIV coreceptor binding site.

Authors:  Julie M Decker; Frederic Bibollet-Ruche; Xiping Wei; Shuyi Wang; David N Levy; Wenquan Wang; Eric Delaporte; Martine Peeters; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Michael S Saag; James A Hoxie; Beatrice H Hahn; Peter D Kwong; James E Robinson; George M Shaw
Journal:  J Exp Med       Date:  2005-05-02       Impact factor: 14.307

View more
  18 in total

1.  Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.

Authors:  Cajetan Dogo-Isonagie; Son Lam; Elena Gustchina; Priyamvada Acharya; Yongping Yang; Syed Shahzad-ul-Hussan; G Marius Clore; Peter D Kwong; Carole A Bewley
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

Review 2.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

3.  Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites.

Authors:  Priyamvada Acharya; Timothy S Luongo; Ivelin S Georgiev; Julie Matz; Stephen D Schmidt; Mark K Louder; Pascal Kessler; Yongping Yang; Krisha McKee; Sijy O'Dell; Lei Chen; Daniel Baty; Patrick Chames; Loïc Martin; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

4.  Design and synthesis of small molecule-sulfotyrosine mimetics that inhibit HIV-1 entry.

Authors:  Cajetan Dogo-Isonagie; Su-Lin Lee; Katheryn Lohith; Hongbing Liu; Sivakoteswara R Mandadapu; Sabrina Lusvarghi; Robert D O'Connor; Carole A Bewley
Journal:  Bioorg Med Chem       Date:  2016-03-03       Impact factor: 3.641

5.  HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism.

Authors:  Ferit Tuzer; Navid Madani; Kantharaju Kamanna; Isaac Zentner; Judith LaLonde; Andrew Holmes; Elizabeth Upton; Srivats Rajagopal; Karyn McFadden; Mark Contarino; Joseph Sodroski; Irwin Chaiken
Journal:  Proteins       Date:  2012-10-26

6.  Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.

Authors:  Gwo-Yu Chuang; Yen-Ting Lai; Jeffrey C Boyington; Cheng Cheng; Hui Geng; Sandeep Narpala; Reda Rawi; Stephen D Schmidt; Yaroslav Tsybovsky; Raffaello Verardi; Kai Xu; Yongping Yang; Baoshan Zhang; Michael Chambers; Anita Changela; Angela R Corrigan; Rui Kong; Adam S Olia; Li Ou; Edward K Sarfo; Shuishu Wang; Winston Wu; Nicole A Doria-Rose; Adrian B McDermott; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

7.  NMR mapping of RANTES surfaces interacting with CCR5 using linked extracellular domains.

Authors:  Einat Schnur; Naama Kessler; Yuri Zherdev; Eran Noah; Tali Scherf; Fa-Xiang Ding; Svetlana Rabinovich; Boris Arshava; Victoria Kurbatska; Ainars Leonciks; Alexander Tsimanis; Osnat Rosen; Fred Naider; Jacob Anglister
Journal:  FEBS J       Date:  2013-04-02       Impact factor: 5.542

8.  Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å cocrystal structure of gp120 and M48U1.

Authors:  Priyamvada Acharya; Timothy S Luongo; Mark K Louder; Krisha McKee; Yongping Yang; Young Do Kwon; John R Mascola; Pascal Kessler; Loïc Martin; Peter D Kwong
Journal:  Structure       Date:  2013-05-23       Impact factor: 5.006

9.  Template-constrained cyclic sulfopeptide HIV-1 entry inhibitors.

Authors:  Jonathan G Rudick; Meg M Laakso; Ashley C Schloss; William F DeGrado
Journal:  Org Biomol Chem       Date:  2013-11-07       Impact factor: 3.876

10.  Molecular mechanism of respiratory syncytial virus fusion inhibitors.

Authors:  Michael B Battles; Johannes P Langedijk; Polina Furmanova-Hollenstein; Supranee Chaiwatpongsakorn; Heather M Costello; Leen Kwanten; Luc Vranckx; Paul Vink; Steffen Jaensch; Tim H M Jonckers; Anil Koul; Eric Arnoult; Mark E Peeples; Dirk Roymans; Jason S McLellan
Journal:  Nat Chem Biol       Date:  2015-12-07       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.